Float & OS1.16 B / 1.59 B
Cash/Shr$0.02
Market Cap & EV—
Short Interest—
Cash$26.06 M
Est. Cash Today$-147.24 M
Off AbilityHigh
Off FreqLow
DilutionLow
Cash NeedHigh
Overall Offering RiskHigh
Warrant Exercise RiskLow
Nasdaq ComplianceHigh
Shares Outstanding History
Cash Position
Cash Position
The company has -12.7 months of cash left based on the quarterly cash burn of $-34.78 M and estimated current cash of $-147.24 M.
Commentary on Financial Condition
“Since our inception, we have incurred significant net losses and negative cash flows from operations. We financed our operations primarily through sales of equity securities, cash receipts under our collaboration arrangements and research and development tax and expenditure credits. From inception through to June 30, 2025, we have raised: ●$545.8 million through collaborative arrangements with Galapagos, Genentech, GSK and Astellas Pharma Inc. (terminated on March 6, 2023);” (from August 2025 filing’s Liquidity and Capital Resources) Filed At: 2025-08-13
Recent Filings
| RW | Form RW | 2026-04-22 |
| SCHEDULE 13G | Form SCHEDULE 13G | 2026-02-17 |
| EFFECT | Form EFFECT | 2025-11-17 |
| SCHEDULE 13G/A | Form SCHEDULE 13G/A | 2025-11-14 |
| 424B3 | Form 424B3 | 2025-11-13 |
| 15-12G | Form 15-12G | 2025-11-13 |
| S-8 POS | Form S-8 POS | 2025-10-28 |
| S-8 POS | Form S-8 POS | 2025-10-28 |
Insights
The company received a deficiency notice from Nasdaq for minimum bid price on September 26, 2025.
· 2025-09-26
The company received a deficiency notice from Nasdaq for market value of listed securities on September 12, 2025.
· 2025-09-12
The company received a deficiency notice from Nasdaq for minimum bid price on August 14, 2025.
· 2025-08-14
The company received a deficiency notice from Nasdaq for minimum bid price on May 1, 2025.
· 2025-05-01
The company received a deficiency notice from Nasdaq for minimum bid price on November 1, 2024.
· 2024-11-01